Skip to main content

July 2023, Vol 13, No 7

Chicago, IL—The presidential theme for the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting was “Partnering With Patients: The Cornerstone of Clinical Care and Research.” In his address during the opening session of the meeting, Eric P. Winer, MD, FASCO, Director, Yale Cancer Center, and Physician-in-Chief, Smilow Cancer Hospital at Yale New Haven, CT, and ASCO’s 2022-2023 President, discussed the importance of physician–patient partnerships for improving healthcare outcomes. Read More ›

At the 10th Annual Cholangiocarcinoma Foundation Conference, Rachna Shroff, MD, MS, Chief, Gastrointestinal Medical Oncology, and Director, Clinical Trials Office, University of Arizona Cancer Center, Tucson, and Madhulika Eluri, MD, Hematology/Oncology Fellow, The University of Texas MD Anderson Cancer Center, Houston, debated whether chemotherapy remains the backbone for cholangiocarcinoma (CCA) treatment or if it is time to move away from this therapeutic strategy. Read More ›

Sarcoma is a general term used to describe a broad group of rare malignancies that develop in the body’s bone and connective tissue, such as fat, muscle, nerves, blood vessels, and the tissue that surrounds bones and joints. It is frequently referred to as the “forgotten cancer” because it comprises a very small percentage of all adult cancers. Read More ›

Ann Arbor, MI—SARC (Sarcoma Alliance for Research Through Collaboration) is proud to announce that it has launched a national, virtual multidisciplinary sarcoma tumor board. Read More ›

At the 10th Annual Cholangiocarcinoma Foundation Conference, Michael E. Lidsky, MD, Assistant Professor, Surgical Oncology, Duke University School of Medicine, Durham, NC, presented his research on a novel model to investigate FGFR signaling and how this information may lead to a new treatment strategy for FGFR2 fusion–positive cholangiocarcinoma (CCA). For patients with advanced CCA, surgery is often not an option, and patients are left with systemic therapy as the only treatment option. Read More ›

Over the years, the therapeutic landscape for cholangiocarcinoma (CCA) has expanded beyond chemotherapy to include immunotherapy and targeted therapies as part of an individualized approach to treatment. At the 10th Annual Cholangiocarcinoma Foundation Conference, Tim F. Greten, MD, Deputy Chief, Thoracic and GI Malignancies Branch; Head, Gastrointestinal Malignancy Section; and Co-Director, National Cancer Institute Center for Cancer Research Liver Cancer Program, Bethesda, MD, discussed novel targets for future CCA treatments coming from translational research studies. Read More ›

Chicago, IL—The addition of the CDK4/6 inhibitor ribociclib (Kisqali) to endocrine therapy significantly improved invasive disease-free survival in patients with hormone receptor (HR)-positive, HER2-negative, early breast cancer, according to interim results of the phase 3 NATALEE trial, which were presented at the 2023 American Society of Clinical Oncology Annual Meeting. Read More ›

Chicago, IL—Interim results from the phase 3 COMMANDS trial demonstrated that first-line treatment with luspatercept-aamt (Reblozyl) increased hemoglobin levels and enabled nearly twice as many patients with transfusion-dependent, lower-risk myelodysplastic syndromes (MDS) to avoid red blood cell transfusions during the first 24 weeks of the study compared with standard-of-care epoetin alfa. Read More ›

Biomarker testing is a necessary tool in the advancing world of precision cancer treatment. According to a new survey released by CancerCare, a leading national cancer support organization, bimarker testing helped physicians tailor therapy for nearly all the respondent patients (93%) whose cancers were tested over the past 3 years. Two in 10 (20%) patients with cancer surveyed were able to avoid unnecessary chemotherapy and/or radiation and 10% became eligible for a clinical trial. Read More ›

Medicine is an essential service. Yet, healthcare providers still need to make enough profit to cover their overhead costs if they want to keep their doors open. That is why it is essential for your business and community that claims are processed accurately and that you get reimbursed for your services. Read More ›

Page 1 of 2